SCHEDULE 13G: Eventide Asset Management Discloses 5.2% Stake in Evolent Health

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has filed a Schedule 13G disclosing beneficial ownership of 5.2% of Evolent Health, Inc.'s Class A Common Stock as of March 31, 2025.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John collectively reported beneficial ownership of 6,077,191 shares of Evolent Health, Inc.'s Class A Common Stock.
• This represents 5.2% of the outstanding Class A Common Stock of Evolent Health, Inc.
• The ownership was reported as of March 31, 2025, the date of the event requiring the filing.
• Eventide Asset Management, LLC holds sole voting and dispositive power over these shares.
• Finny Kuruvilla and Robin C. John share voting and dispositive power over the same shares, indicating a group filing under Rule 13d-1(k)(1).
• The shares are held by Eventide as an investment adviser for various accounts, including Eventide Gilead Fund (4,264,670 shares, 3.7%), Eventide Healthcare & Life Sciences Fund (1,778,479 shares, 1.5%), and Eventide's separately managed accounts (34,042 shares, 0.0%).
• The acquisition and holding of these securities are stated to be in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) reporting beneficial ownership, which is a neutral, factual disclosure without explicit positive or negative implications for the issuer's performance or outlook.

Positives

• Significant institutional investment by Eventide Asset Management, LLC, holding 5.2% of Evolent Health's Class A Common Stock, indicates confidence from a notable investment adviser.

Future Outlook

NA

Industry Context

This filing reflects a significant investment by Eventide Asset Management in Evolent Health, Inc., a company operating in the healthcare technology sector, indicating continued institutional interest in the industry.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence in the company's prospects.

Key Dates

Keywords

Evolent Health, Eventide Asset Management, Schedule 13G, beneficial ownership, institutional investor, Class A Common Stock, healthcare technology, investment